Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical Co. (NASDAQ:DERM) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 83,800 shares, an increase of 6.5% from the January 15th total of 78,700 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 80,800 shares, the short-interest ratio is currently 1.0 days.

Journey Medical Price Performance

NASDAQ:DERM traded down $0.10 during trading hours on Tuesday, hitting $5.14. 39,963 shares of the stock were exchanged, compared to its average volume of 56,683. Journey Medical has a 52-week low of $2.85 and a 52-week high of $6.89. The firm’s fifty day moving average price is $4.44 and its 200 day moving average price is $5.04. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The company has a market cap of $107.37 million, a P/E ratio of -5.47 and a beta of 1.03.

Institutional Investors Weigh In On Journey Medical

Several large investors have recently bought and sold shares of the company. Tang Capital Management LLC purchased a new stake in Journey Medical during the 4th quarter worth approximately $6,747,000. Cetera Investment Advisers increased its stake in Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after buying an additional 2,478 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Journey Medical during the 4th quarter worth approximately $174,000. Kovitz Investment Group Partners LLC increased its stake in Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after buying an additional 13,105 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Journey Medical during the 4th quarter worth approximately $80,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.